Skip to content
The Nexus
DossierENTITY

Cytiva

Coverage of Cytiva in the Nexus archive.

Earliest in view: Jul 16 · 00:00 UTCMost recent: Jul 27 · 11:40 UTC
Co-mentioned in this coverage
Paul Belcherperson2AI-driven drug discoverytopic1Eroom’s Lawtopic1hit identificationtopic1drug developmenttopic1clinical phasetopic1Henrik Ihreperson1Artificial Intelligencetopic1drug purificationtopic1chromatography resintopic1bioreactorstopic1
Recent coverage
  • HEALTHJul 27 · 11:40 UTCMIT TECHNOLOGY REVIEW
    Closing the data loop in AI-driven drug discovery

    AI is being used to accelerate drug discovery by identifying and optimizing chemical compounds more efficiently, reducing costs and timelines. However, AI-generated candidates still require lab validation due to limitations in predicting compound kinetics and developability.

  • SCIENCEJul 16 · 00:00 UTCNEW SCIENTIST
    Drug discovery Is changing. Drug development must change too.

    Artificial intelligence and big data are accelerating drug discovery, creating a mismatch with existing manufacturing capabilities for safe mass production. Experts from Cytiva highlight challenges in scaling purification processes from lab to industrial scales, emphasizing the risks and complexities in translating promising drug candidates to market-ready therapies.